Medicago has signed a memorandum of understanding (MOU) with Ajanta Pharma, to negotiate an agreement to commercialize Medicago’s pandemic and seasonal influenza VLP-based vaccines in India and other territories.
Under the terms of the MOU, the parties will evaluate and select an optimal deal structure with the objective of formalizing a definitive agreement within 90 days.
Andy Sheldon, president and CEO of Medicago, said: We are delighted to be collaborating with Ajanta. This MOU is consistent with our strategy to provide countries worldwide with a rapid, affordable and effective solution for the supply of vaccines within their borders.
Frederic Ors, vice president of Business Development at Medicago, said: This potential partnership with Ajanta will provide Medicago with another near-term commercial opportunity to broaden the deployment of our novel pandemic and seasonal influenza VLP vaccines and continue to validate our proprietary plant-based technologies. We intend to continue to pursue business opportunities of this nature and expand our footprint in regions that lack influenza vaccine manufacturing capabilities.